Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) is a key regulator in cellular signaling pathways because its dysregulation has been implicated in various pathological conditions, including cancers and developmental disorders. Despite its importance, the molecular basis of SHP2’s regulatory mechanism remains poorly understood, hindering the development of effective targeted therapies. In this study, we utilized the high-specificity monobody Mb11 to investigate its interaction with the SHP2 phosphatase domain (PTP) using multiple replica molecular dynamics simulations. Our analyses elucidate the precise mechanisms through which Mb11 achieves selective recognition and stabilization of the SHP2-PTP domain, identifying key residues and interaction networks essential for its high binding specificity and regulatory dynamics. Furthermore, the study highlights the pivotal role of residue C459 in preserving the structural integrity and functional coherence of the complex, acting as a central node within the interaction network and underpinning its stability and efficiency. These findings have significantly advanced the understanding of the mechanisms underlying SHP2’s involvement in disease-related signaling and pathology while simultaneously paving the way for the rational design of targeted inhibitors, offering significant implications for therapeutic strategies in SHP2-associated diseases and contributing to the broader scope of precision medicine.
3 April 2025 in Physical Chemistry Chemical Physics
This study elucidates the molecular mechanism by which Mb13 selectively binds to SHP2-PTP by stabilizing polar interactions and reducing the binding free energy, providing a theoretical foundation for the design of SHP2-targeted anticancer drugs.
21 May 2026 in Clinical and Translational Medicine
Immunotherapy has emerged as a transformative approach to cancer treatment, yet its clinical efficacy in most solid tumours remains limited, largely because of the immunosuppressive tumour microenvironment (TME). In this context, glucose metabolic reprogramming has emerged as a central determinant of tumour progression and immune dysfunction because it not only sustains the proliferative and biosynthetic demands of malignant cells but also profoundly reshapes immune responses within the TME. Effective antitumour immunity depends on the metabolic adaptability of effector immune cells, particularly the coordinated use of glycolysis and oxidative phosphorylation to support activation, expansion and cytotoxic function. Under the nutrient‐deprived, hypoxic and acidic conditions that characterize the TME, however, these cells undergo metabolic restriction that progressively drives dysfunction and exhaustion. By contrast, regulatory T cells, tumour‐associated macrophages and myeloid‐derived suppressor cells exhibit greater metabolic plasticity, enabling their persistence and reinforcing their immunosuppressive activity. In this review, we discuss how glucose metabolic reprogramming drives immune dysfunction through several interconnected processes, including glucose competition, lactate accumulation, reciprocal regulation between glucose metabolism and cytokine signalling, glycosylation remodelling and dynamic crosstalk with immune checkpoint signalling. Collectively, these mechanisms position glucose metabolism as a pivotal immunometabolic axis linking tumour bioenergetics to immune evasion and therapeutic resistance. A deeper understanding of this regulatory network may inform the rational development of combination strategies that integrate metabolic intervention with immunotherapy, ultimately improving therapeutic precision and the durability of clinical benefit. Highlight: Glucose metabolic reprogramming is a central driver of immunosuppression in the tumour microenvironment. Glucose competition establishes a selective bioenergetic hierarchy that constrains antitumour immunity. Lactate accumulation and reciprocal regulation with cytokine signalling amplify immunosuppressive signalling and reinforce immune exclusion. Glycosylation remodelling translates altered metabolic flux into sustained changes in receptor stability, ligand recognition and checkpoint responsiveness. Dynamic crosstalk with immune checkpoint signalling entrenches chronic immune dysfunction and therapeutic resistance.
6 February 2024 in Computers in Biology and Medicine
Hepatocellular carcinoma (HCC) is a highly lethal malignancy worldwide and is characterized by a low rate of early detection. In recent years, immune checkpoint inhibitors (ICIs) have been increasingly incorporated into the management of advanced HCC. However, overall response rates remain modest, indicating that immune checkpoint blockade alone is insufficient to overcome the intrinsic immunosuppressive state of HCC. Advances in metabolomics have provided new insights into early detection and therapeutic response evaluation in HCC and have underscored the functional significance of tumor metabolism in disease progression. The metabolic landscape of the HCC tumor microenvironment is predominantly shaped by alterations in glucose, lipid, and amino acid metabolism. These pathways not only support tumor cell energy production and biosynthetic demands but also reprogram local nutrient availability and metabolite composition, thereby continuously reshaping the immune milieu. This metabolic remodeling impairs effector immune cell function and facilitates the establishment and maintenance of immunosuppressive cell populations. Accordingly, this review summarizes the role of metabolic reprogramming in tumor immune regulation during HCC development, with a focus on the heterogeneity of metabolic reprogramming and immune regulation across distinct etiological backgrounds. Systematic elucidation of immunometabolic crosstalk may enhance the precision and translational potential of combination therapeutic strategies.